What happens when you take your 2nd dose of Wegovy?

Why does the dose start so low and then step up?

Wegovy (semaglutide) is a GLP-1 receptor agonist — it mimics a gut hormone that slows gastric emptying and signals fullness to the brain. Those effects are real from the first injection, but at 0.25 mg the dose is calibrated primarily to let your digestive system adapt rather than to drive weight loss at full pace. The starter dose is the body's introduction, not the working level.

The 0.5 mg second dose arrives four weeks later and nudges the pharmacological effect upward. Most people find appetite suppression is noticeably stronger here, smaller portions feel sufficient, and the instinct to snack between meals quietens. That said, the GI side effects that may have been mild at 0.25 mg can intensify temporarily after the step up. Nausea is the most commonly reported; diarrhoea, constipation, burping and reflux also appear in the trial data. These effects are described in the NHS semaglutide medicines page and typically settle within a week or two as the body adjusts to the new level.

The titration schedule exists precisely because of this dose-sensitivity: moving too quickly tends to amplify side effects without meaningful extra benefit at that stage. Your prescriber controls the pace, and that oversight matters.

What does the full Wegovy escalation ladder look like?

The licensed UK titration pathway runs: 0.25 mg (weeks 1–4), 0.5 mg (weeks 5–8), 1.0 mg (weeks 9–12), 1.7 mg (weeks 13–16), then 2.4 mg as the standard maintenance dose from week 17 onward. Each step is roughly four weeks apart. The full dose range for Wegovy now also includes 7.2 mg as a higher maintenance option, approved by the MHRA in early 2026, though the starting point and graduated path remain the same.

For most people, the second dose at 0.5 mg is where the medicine starts to feel purposeful rather than preliminary. Appetite changes become easier to work with, and the rhythm of once-weekly injections becomes familiar. Some people, particularly those who found the 0.25 mg phase rough, wonder whether it's safe to stay at 0.5 mg longer. That's a conversation for your prescriber, not a decision to make alone.

Information on what tends to happen during the second month of Wegovy (when many people transition from 0.5 mg to 1.0 mg) covers the practical side of that step in more detail. The pen and dose format also changes as you climb the schedule, so understanding what your pen contains at each stage is worth a few minutes of your time.

Are side effects at the second dose a sign something is wrong?

Not usually. The pattern described in the STEP 1 clinical trial (published in the New England Journal of Medicine) showed gastrointestinal events were most common in the early weeks of treatment and around dose increases, with the majority being mild to moderate in severity. Nausea that peaks for a few days after the 0.5 mg injection and then fades is part of the expected pattern.

There are, however, symptoms that warrant prompt medical attention regardless of which dose you are on. Severe, persistent abdominal pain that extends toward the back (with or without vomiting) should not be waited out; this is the presentation the MHRA flagged in a January 2026 Drug Safety Update in relation to acute pancreatitis as a known, though infrequent, risk with GLP-1 medicines. Signs of a serious allergic reaction (swelling of the face or throat, difficulty breathing) require emergency care. Your prescriber and the Patient Information Leaflet that comes with your pen are the definitive reference for a complete list of warning signs.

For a thorough look at what the most common doses produce in terms of side effect profiles, or if you're weighing whether a higher dose might be appropriate for you later in treatment, both are worth reading once you're settled at 0.5 mg.

Can you skip straight to a higher dose if 0.5 mg feels fine?

The short answer is: not without clinical approval. The titration schedule isn't just about tolerability, it also reflects how the medicine's pharmacokinetics work. Semaglutide accumulates in the body over weeks; jumping doses too quickly can produce a sharper spike in side effects without a proportional acceleration in outcomes. The prescriber reviewing your care is best placed to assess whether your tolerance warrants moving faster or whether there's value in holding a dose a little longer.

This is one of the things a Wegovy treatment overview is useful for before starting: understanding that the titration is a feature, not a formality. If cost is a consideration at this stage, the cost of Wegovy in the UK is explained in context of what legitimate prescribing involves, a useful read before comparing providers. Ultimately, any dose question that isn't answered by your Patient Information Leaflet should go to your prescriber directly. If you're not yet under clinical care and want to explore whether Wegovy is suitable for you, you can start a free consultation with one of our GPhC-registered prescribers.